Current disease status-First occurrence of the leukemia Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the leukemia Posts on Medivizor

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Posted by on Jan 23, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia.  This study concluded that this combination is safe and effective in these patients.   Some...

Read More

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...

Read More

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Posted by on Oct 3, 2021 in Leukemia | 0 comments

In a nutshell This study examined the association between long-term use of three different tyrosine kinase inhibitors (TKIs) and the occurrence of vascular (blood vessel) adverse events (side effects; VAEs) in patients with chronic myeloid leukemia (CML). The data showed a possibly higher risk of developing VAEs when patients with CML were...

Read More

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years....

Read More

Comparing intensive and less-intensive treatment for older patients with acute myeloid leukemia

Comparing intensive and less-intensive treatment for older patients with acute myeloid leukemia

Posted by on May 9, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare the safety and effectiveness of intensive and less-intensive therapy for older adults with acute myeloid leukemia (AML).  This study concluded that intensive therapy may lead to better outcomes for these patients when compared to less-intensive therapy.  Some background Older patients with...

Read More

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2  x 4 doses) with or without blinatumomab (Blincyto) in patients with...

Read More

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Posted by on Feb 26, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term survival outcomes of treosulfan (Trecondi)-based versus busulfan (Myleran)-based conditioning treatment in patients with acute myeloid leukemia. This study concluded that treosulfan-based conditioning treatment may have better outcomes for these patients.   Some background...

Read More

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Posted by on Jan 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the GIMEMA LAL-1308 treatment protocol in young patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.   This study concluded that this treatment protocol was safe and effective for these patients.  Some background Adolescents and young adults...

Read More